

18 Jul 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: setback for a COVID-19 candidate; Chinese biotechs move into mRNA; Sanofi's strategic moves into hemophilia; Orion's deal for its novel prostate cancer candidate; and Roche's evolving approach to platform deals.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 15 July 2022, including: a setback for a COVID candidate; Chinese biotechs move into mRNA; [Sanofi](#) builds hemophilia presence; [Orion Corporation](#)'s deal for its novel prostate cancer candidate; and [Roche Holding AG](#)'s evolving approach to platform deals.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Humanigen Isn't Throwing In The Towel On Lenzilumab For COVID-19 Just Yet](#)" - Scrip, 13 Jul, 2022.)

(Also see "[BeiGene Latest Chinese Biotech To Double Down On mRNA For Cancer](#)" - Scrip, 11 Jul, 2022.)

(Also see "[Sanofi Has One Hemophilia Winner On It Hands – But Fitusiran's Fate Remains Unclear](#)" - Scrip, 11 Jul, 2022.)

(Also see "[\*Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal\*](#)" - Scrip, 13 Jul, 2022.)

(Also see "[\*Roche Partnering Finds Upfront Fee Relief In Current Market\*](#)" - Scrip, 8 Jul, 2022.)

[Click here to explore this interactive content online](#) ✎